A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth…
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
Zogenix shares were crushed on Tuesday after the firm provided an update from the FDA regarding Fintepla for the treatment of seizures associated with Dravet syndrome.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Friday include Apple, Caterpillar, Costco, GW Pharmaceuticals, NXP Semiconductors, Southwest Airlines, Teva Pharmaceutical, Ulta Beauty and Wells Fargo.
Zogenix shares made a solid gain on Thursday after the company announced positive results from its late-stage seizure trial.
Chris Lange The top analyst upgrades, downgrades and other research calls from Monday include AECOM, Ciena, Evoqua Water Tech, Funko, GlaxoSmithKline and Square.
Zogenix saw its shares more than double early on Friday after the company reported positive top-line results from its most recent late-stage trial in the treatment of Dravet syndrome.
Chris Lange All three of these specialty pharmaceutical stocks come with a fair share of risk but provide big upside potential as well.
Aggressive traders looking for solid ideas with big upside from all over Wall Street will like a new research note from Stifel, which features four stocks to buy with huge potential.
Stocks are still very close to all-time highs, and this bull market is now six years old. It turns out that some stocks made unusual moves last week.
Zogenix has announced an agreement for the sale of its Zohydro ER (hydrocodone bitartrate) business to Pernix for $100 million.
Chris Lange Analysts who cover low-priced and small-cap stocks often predict upside of 50%, 100% or much more. You just don't see calls like that in Dow and S&P 500 stocks.
Oppenheimer's official rating on Zogenix remains Outperform, but what stands out is that the $2.50 price target implies that shares can more than double.
Jon C. Ogg Zogenix has traded like a company that is about to implode. Its highly controversial Zohydro has been getting inquiries into how it was approved for marketing despite an FDA panel being against…
Jon C. Ogg 
